AlphaCrest Capital Management LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 158 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.

Quarter-by-quarter ownership
AlphaCrest Capital Management LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$334,000
-28.2%
14,484
-23.1%
0.02%
-51.3%
Q4 2020$465,000
+36.8%
18,823
+129.8%
0.04%
+5.4%
Q3 2020$340,000
+17.2%
8,191
+35.3%
0.04%
-22.9%
Q2 2020$290,000
-15.2%
6,054
+11.4%
0.05%
+17.1%
Q1 2020$342,000
-45.3%
5,434
+7.8%
0.04%
-19.6%
Q4 2019$625,000
-3.5%
5,041
-48.4%
0.05%
+30.8%
Q3 2019$648,0009,7610.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders